Enliven Therapeutics Inc (NASDAQ: ELVN) on Monday, plunged -14.60% from the previous trading day, before settling in for the closing price of $23.42. Within the past 52 weeks, ELVN’s price has moved between $13.30 and $29.78.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 19.02%. The company achieved an average annual earnings per share of -2.00%. With a float of $41.91 million, this company’s outstanding shares have now reached $59.23 million.
Enliven Therapeutics Inc (ELVN) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Enliven Therapeutics Inc is 29.26%, while institutional ownership is 76.04%. The most recent insider transaction that took place on Oct 20 ’25, was worth 276,025. In this transaction CHIEF SCIENTIFIC OFFICER of this company sold 12,500 shares at a rate of $22.08, taking the stock ownership to the 915,188 shares. Before that another transaction happened on Oct 17 ’25, when Company’s PRESIDENT AND CEO sold 12,500 for $21.33, making the entire transaction worth $266,654. This insider now owns 902,892 shares in total.
Enliven Therapeutics Inc (ELVN) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.48 earnings per share (EPS) for the period topping the consensus outlook (set at -0.5) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.5 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -2.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -19.62% during the next five years compared to 19.02% growth over the previous five years of trading.
Enliven Therapeutics Inc (NASDAQ: ELVN) Trading Performance Indicators
Enliven Therapeutics Inc (ELVN) is currently performing well based on its current performance indicators. A quick ratio of 32.58 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.00, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach -2.21 in one year’s time.
Technical Analysis of Enliven Therapeutics Inc (ELVN)
The latest stats from [Enliven Therapeutics Inc, ELVN] show that its last 5-days average volume of 0.91 million was superior to 0.41 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 66.02%.
During the past 100 days, Enliven Therapeutics Inc’s (ELVN) raw stochastic average was set at 35.67%, which indicates a significant increase from 26.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.41 in the past 14 days, which was higher than the 1.26 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.41, while its 200-day Moving Average is $20.16. Now, the first resistance to watch is $22.76. This is followed by the second major resistance level at $25.53. The third major resistance level sits at $27.74. If the price goes on to break the first support level at $17.78, it is likely to go to the next support level at $15.57. Assuming the price breaks the second support level, the third support level stands at $12.80.
Enliven Therapeutics Inc (NASDAQ: ELVN) Key Stats
Market capitalization of the company is 1.18 billion based on 59,236K outstanding shares. Right now, sales total 0 K and income totals -89,020 K. The company made 0 K in profit during its latest quarter, and -25,340 K in sales during its previous quarter.
